The data for NPS PHARMA UK LIMITED shows a steady increase in the average time taken to pay invoices over the past three periods. In the first period (Jan 2018 - Jun 2018), the average time was not available. In the second period (Jul 2018 - Dec 2018), it increased to 52.3 days. And in the third period (Jan 2019 - Jun 2019), it further increased to 60 days.
The data also shows some volatility in the percentage of invoices paid within 30 days. In the first period, the percentage was not available. In the second period, it was 70.2%, but in the third period, it decreased to 60%. On the other hand, the percentage of invoices paid between 31-60 days remained relatively stable at around 20%, while the percentage of invoices paid later than 60 days increased from 10.1% in the second period to 19.8% in the third period.
Overall, the data for NPS PHARMA UK LIMITED shows a steady increase in the average time taken to pay invoices and a slight decrease in the percentage of invoices paid within 30 days. The percentage of invoices paid between 31-60 days remained relatively stable, while the percentage of invoices paid later than 60 days increased. This suggests that the company may be facing some financial difficulties or cash flow issues.
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2018 - 31 Dec 2018 | 28 Jan 2019 | |||||
| 01 Jan 2018 - 30 Jun 2018 | 27 Jul 2018 |
NPS Pharma UK Limited is a pharmaceutical company based in the United Kingdom. The company focuses on developing and providing innovative and sustainable solutions for rare and serious medical conditions. They are committed to making a positive impact on patients' lives, the environment, and society as a whole.
The company's sustainability program is aligned with their core values and aims to reduce their carbon footprint, promote ethical and responsible practices, and prioritize the well-being of their employees. This includes implementing eco-friendly measures and supporting various community initiatives.
NPS Pharma UK Limited offers a range of products and services that cater to rare diseases, such as hypoparathyroidism and acromegaly. They have a team of dedicated professionals who are committed to delivering high-quality, safe, and effective treatments to patients in need.
Some key people in the company include the Managing Director, who oversees the overall operations, and the Director of Research and Development, who leads the team in developing new treatments. The company also has a team of experienced scientists, researchers, and healthcare professionals who work together to achieve their goals.
For more information, interested parties can visit NPS Pharma UK Limited's website at www.npspharmaceuticals.co.uk. The company's registered office address is located at 40 Holborn Viaduct, London, EC1N 2PZ, United Kingdom. NPS Pharma UK Limited is committed to promoting sustainability and making a positive impact in the pharmaceutical industry.